



## **LIALDA™ (mesalamine) mit MMX™ Technology auf dem Markt**

**Lainate, Italien – 20. März 2007 –** (SWX: COPN) Cosmo Pharmaceuticals S.p.A., ein Spezialitätenpharmaunternehmen, das sich zum Ziel gesetzt hat, weltweit führend für optimierte Therapien zur Behandlung bestimmter Magen-Darm-Erkrankungen zu werden, gibt heute bekannt, dass das am weitesten entwickelte Produkt, LIALDA™/MEZAVANT™, ein Medikament zur Behandlung von leichter bis mittelschwerer Colitis ulcerosa, nun in den USA auf dem Markt erhältlich ist. LIALDA™/MEZAVANT™ hat von der US-amerikanischen Arzneimittelbehörde FDA am 16. Januar 2007 die Marktzulassung erhalten.

Das Medikament wurde von Cosmo weltweit an Giuliani und Shire plc. lizenziert. Shire verkauft es nun gegen Rezept in Dosierungen von 2.4 g/Tag und 4.8 g/Tag an Patienten zur oralen Verabreichung. Die ganze vom Arzt verschriebene Dosis LIALDA™/MEZAVANT™ kann auf einmal eingenommen werden, wogegen andere erhältliche Mesalamine drei- bis viermal täglich eingenommen werden müssen, mit bis zu 16 Tabletten pro Tag. Eine Studie hat gezeigt, dass Patienten, die Mesalamine-Medikamente nicht gemäss den ärztlichen Vorschriften einnehmen, einem fünfmal grösseren Risiko eines Aufflackerens der Krankheit, einer ernsthaften Verschlechterung der Symptome, ausgesetzt sind.

Mauro Ajani, CEO von Cosmo, kommentiert: "LIALDA™ ist das erste Medikament mit der von Cosmo entwickelten MMX™ Technologie. Sie gibt die aktive Substanz in hoher Konzentration und kontrolliert direkt in das Lumen des Darms ab, dem Ort der Entzündung. Diese innovative Technologie bringt für die Patienten mit Colitis ulcerosa eine deutliche Verbesserung."

### **Über Cosmo Pharmaceuticals**

Cosmo will ein weltweit führendes Spezialitätenpharmaunternehmen für optimierte Therapien für Magen-Darm-Erkrankungen werden. Die geschützte klinische Entwicklungspipeline von Cosmo fokussiert sich auf innovative Behandlungen von entzündlichen Darmerkrankungen (IBD), wie zum Beispiel Colitis ulcerosa und die Morbus-Crohn-Krankheit sowie Dickdarminfektionen. Das am weitesten entwickelte Produkt von Cosmo ist LIALDA™/MEZAVANT™, ein Medikament zur Behandlung von leichter bis mittelschwerer Colitis ulcerosa, das weltweit an Giuliani und Shire plc. lizenziert wurde. Die geschützte MMX™-Technologie ist für die Produktpipeline des Unternehmens zentral. Sie wurde auf der Basis der Erfahrungen bei der Formulierung und Herstellung von Arzneimitteln zur Behandlung von Magen- Darm-Erkrankungen für internationale Kunden in den GMP-konformen (Good Manufacturing Practice) Produktionsstätten in Lainate, Italien, entwickelt. Weitere Informationen auf [www.cosmopharmaceuticals.com](http://www.cosmopharmaceuticals.com)

Not for release, publication or distribution in the United States of America,  
Canada, Japan or Australia

## **Weitere Informationen**

Dr. Chris Tanner, CFO und Head of Investor Relations  
Cosmo Pharmaceuticals  
Tel.: +39 02 9333 7614

This document does neither constitute an offer to buy or to subscribe to shares of COSMO Pharmaceuticals S.p.A. nor a prospectus within the meaning of the applicable Swiss law. Investors should make their decision to buy or to subscribe to shares solely based on the official offering and listing prospectus. Investors are furthermore advised to consult their bank or financial adviser.

This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This document is not being issued in the United States of America and should not be distributed or otherwise transmitted in the United States or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the Securities Act )) or publications with a general circulation in the United States. This document does not constitute an offer or invitation to subscribe for or purchase any securities. The securities of COSMO Pharmaceuticals S.p.A. have not been and will not be registered under the Securities Act and are not being offered or sold in the United States or to U. S. persons. Securities may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from the registration requirements of the Securities Act.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom within the meaning of the Public Offers of Securities Regulations 1995. No prospectus offering securities to the public will be published in the United Kingdom.

This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order ) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as relevant persons ). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This document constitutes neither an offer to sale nor an invitation or solicitation to buy securities in Italy and does not constitute a public offering under the meaning of sections 1, item t) and 94(1) of the Legislative Decree n. 58 of 24 February 1998. The securities referred to herein cannot be offered, distributed, marketed, promoted or solicited in Italy to investors other than "Professional Investors" as defined by Articles 25 and 31(2) of Consob's Regulation No. 11522 of 1 July 1998, as amended, (including, *inter alia*, investment firms, ("SIMs"), banks authorized to provide investment services, stockbrokers, SICAVs, pension funds, insurance companies, entities enrolled in the register referred to in Articles 106, 107 and 113 of the Legislative Decree 385 of 1 September 1993, financial salesmen, individuals possessing the professionalism requirements referred to in Article 31(2) of the Regulation No. 11522, legal persons stating to have specific expertise and experience in financial transactions) without Consob's prior authorization. COSMO Pharmaceuticals S.p.A. intends neither to carry out a public offering of the securities in Italy nor to apply for the relevant Consob's authorization. This press release is not directed to Italian residents other than Professional Investors as defined above.

Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the Prospectus Directive ) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.

The securities described herein will be offered publicly in Switzerland only. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

Stabilization/FSA